author-photo

Rebecca Sophie Kristeleit

University College London

119

Papers

2081

Citations

Citation Trend

Filter By

Papers (74) Sort By

Journal Conference Others

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors

2019 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (15)
Mainstreamed genetic testing for women with ovarian cancer: first-year experience

2019 Journal of Medical Genetics
Show All
- Source
- Cite
- Save
Citations (26)
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

2018 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (30)
A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of the dual MET kinase/OCT2 inhibitor, OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Clear cell ovarian cancer (CCOC): 115 patient (pt) series showing access to experimental therapy may improve response rates in recurrent disease.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
975PClear cell ovarian cancer (CCOC): Predicting risk of relapse (ROR)

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Phase 1/2a study of once daily oral BAL101553, a novel tumor checkpoint controller (TCC), in adult patients with advanced solid tumors.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
932OPhase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (11)
988TiPARIEL4: An international, randomised phase 3 study of the PARP inhibitor rucaparib vs chemotherapy for the treatment of BRCA-mutated, relapsed, high-grade ovarian cancer

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)